ReviewVeterinary research communications2026
Differential diagnosis of microcytic hypochromic anemia in dogs: the role of hepcidin and reticulocyte hemoglobin indices.
Review in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microcytic hypochromic anemia in dogs represents a persistent diagnostic challenge, particularly when differentiating between absolute iron deficiency and inflammation-driven functional iron restriction. Conventional biomarkers, including serum iron and ferritin, present important limitations in terms of sensitivity, specificity, and temporal resolution, restricting their ability to accurately reflect dynamic changes in iron metabolism. This review critically evaluates the diagnostic performance and clinical relevance of hepcidin and reticulocyte hemoglobin indices (CHr/RET-He) as advanced biomarkers of iron-restricted erythropoiesis in dogs. Reticulocyte indices provide a dynamic and near real-time assessment of iron availability at the level of erythropoiesis, enabling early detection of iron-restricted states and monitoring of therapeutic response. However, their diagnostic utility is limited by an inability to discriminate between underlying etiological mechanisms. In contrast, hepcidin, the central regulator of systemic iron homeostasis, provides mechanistic insight into iron metabolism. Its circulating concentrations decrease in absolute iron deficiency and increase in inflammation-mediated iron sequestration, thereby potentially facilitating etiological differentiation. Despite its diagnostic potential, clinical application remains limited by methodological variability, lack of assay standardization, and incomplete reference intervals in canine populations. The integration of functional biomarkers (CHr/RET-He) with a regulatory biomarker (hepcidin) is proposed as a complementary and physiologically grounded approach. This combined strategy may enhance diagnostic accuracy, support etiological classification, and facilitate clinical decision-making; however, its diagnostic performance has not yet been sufficiently validated in canine patients, and further prospective studies are required before routine clinical implementation can be recommended.
Indexed as
Identifiers
42728486What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.